Skip to main content
Top
Published in: Osteoporosis International 3/2012

Open Access 01-03-2012 | Original Article

Calibration of FRAX ® 3.1 to the Dutch population with data on the epidemiology of hip fractures

Authors: A. Lalmohamed, P. M. J. Welsing, W. F. Lems, J. W. G. Jacobs, J. A. Kanis, H. Johansson, A. De Boer, F. De Vries

Published in: Osteoporosis International | Issue 3/2012

Login to get access

Abstract

Summary

The FRAX tool has been calibrated to the entire Dutch population, using nationwide (hip) fracture incidence rates and mortality statistics from the Netherlands. Data used for the Dutch model are described in this paper.

Introduction

Risk communication and decision making about whether or not to treat with anti-osteoporotic drugs with the use of T-scores are often unclear for patients. The recently developed FRAX models use easily obtainable clinical risk factors to estimate an individual's 10-year probability of a major osteoporotic fracture and hip fracture that is useful for risk communication and subsequent decision making in clinical practice. As of July 1, 2010, the tool has been calibrated to the total Dutch population. This paper describes the data used to develop the current Dutch FRAX model and illustrates its features compared to other countries.

Methods

Age- and sex-stratified hip fracture incidence rates (LMR database) and mortality rates (Dutch national mortality statistics) for 2004 and 2005 were extracted from Dutch nationwide databases (patients aged 50+ years). For other major fractures, Dutch incidence rates were imputed, using Swedish ratios for hip to osteoporotic fracture (upper arm, wrist, hip, and clinically symptomatic vertebral) probabilities (age- and gender-stratified). The FRAX tool takes into account age, sex, body mass index (BMI), presence of clinical risk factors, and bone mineral density (BMD).

Results

Fracture incidence rates increased with increasing age: for hip fracture, incidence rates were lowest among Dutch patients aged 50–54 years (per 10,000 inhabitants: 2.3 for men, 2.1 for women) and highest among the oldest subjects (95–99 years; 169 of 10,000 for men, 267 of 10,000 for women). Ten-year probability of hip or major osteoporotic fracture was increased in patients with a clinical risk factor, lower BMI, female gender, a higher age, and a decreased BMD T-score. Parental hip fracture accounted for the greatest increase in 10-year fracture probability.

Conclusion

The Dutch FRAX tool is the first fracture prediction model that has been calibrated to the total Dutch population, using nationwide incidence rates for hip fracture and mortality rates. It is based on the original FRAX methodology, which has been externally validated in several independent cohorts. Despite some limitations, the strengths make the Dutch FRAX tool a good candidate for implementation into clinical practice.
Literature
2.
go back to reference Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767PubMedCrossRef Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761–1767PubMedCrossRef
3.
go back to reference Morrison RS, Chassin MR, Siu AL (1998) The medical consultant's role in caring for patients with hip fracture. Ann Intern Med 128:1010–1020PubMed Morrison RS, Chassin MR, Siu AL (1998) The medical consultant's role in caring for patients with hip fracture. Ann Intern Med 128:1010–1020PubMed
4.
go back to reference Wolinsky FD, Fitzgerald JF, Stump TE (1997) The effect of hip fracture on mortality, hospitalization, and functional status: a prospective study. Am J Public Health 87:398–403PubMedCrossRef Wolinsky FD, Fitzgerald JF, Stump TE (1997) The effect of hip fracture on mortality, hospitalization, and functional status: a prospective study. Am J Public Health 87:398–403PubMedCrossRef
5.
go back to reference Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397PubMedCrossRef Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397PubMedCrossRef
6.
go back to reference Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046PubMedCrossRef Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046PubMedCrossRef
7.
go back to reference Johansson H, Kanis JA, McCloskey EV, Oden A, Devogelaer JP, Kaufman JM et al (2010) A FRAX(R) model for the assessment of fracture probability in Belgium. Osteoporos Int 22:453–461PubMedCrossRef Johansson H, Kanis JA, McCloskey EV, Oden A, Devogelaer JP, Kaufman JM et al (2010) A FRAX(R) model for the assessment of fracture probability in Belgium. Osteoporos Int 22:453–461PubMedCrossRef
8.
go back to reference Bouter LM, van Dongen MCJM, Zielhuis GA (2005) Epidemiologisch onderzoek, 5th edn. Bohn Stafleu van Loghum, Nederland, p 41 Bouter LM, van Dongen MCJM, Zielhuis GA (2005) Epidemiologisch onderzoek, 5th edn. Bohn Stafleu van Loghum, Nederland, p 41
9.
go back to reference de Bruin A, Ariel A, Verweij G, Israëls A (2009) Methode van bijschatten van StatLinetabel Ziekenhuispatiënten naar diagnose. Statistics Netherlands (CBS), Den Haag de Bruin A, Ariel A, Verweij G, Israëls A (2009) Methode van bijschatten van StatLinetabel Ziekenhuispatiënten naar diagnose. Statistics Netherlands (CBS), Den Haag
10.
go back to reference Verdel BM, Souverein PC, Egberts TC, van Staa TP, Leufkens HG, de Vries F (2010) Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone 47:604–609PubMedCrossRef Verdel BM, Souverein PC, Egberts TC, van Staa TP, Leufkens HG, de Vries F (2010) Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone 47:604–609PubMedCrossRef
11.
go back to reference Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, de Vries F (2009) Antipsychotic use and the risk of hip/femur fracture: a population-based case–control study. Osteoporos Int 20:1499–1506PubMedCrossRef Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, de Vries F (2009) Antipsychotic use and the risk of hip/femur fracture: a population-based case–control study. Osteoporos Int 20:1499–1506PubMedCrossRef
12.
go back to reference Pouwels S, Lalmohamed A, van Staa T, Cooper C, Souverein P, Leufkens HG et al (2010) Use of organic nitrates and the risk of hip fracture: a population-based case–control study. J Clin Endocrinol Metab 95:1924–1931PubMedCrossRef Pouwels S, Lalmohamed A, van Staa T, Cooper C, Souverein P, Leufkens HG et al (2010) Use of organic nitrates and the risk of hip fracture: a population-based case–control study. J Clin Endocrinol Metab 95:1924–1931PubMedCrossRef
13.
go back to reference Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt BJ, Leufkens HG et al (2010) Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case–control study. Osteoporos Int 22:903–910PubMedCrossRef Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt BJ, Leufkens HG et al (2010) Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case–control study. Osteoporos Int 22:903–910PubMedCrossRef
14.
go back to reference Pouwels S, Lalmohamed A, Leufkens B, de Boer A, Cooper C, van Staa T et al (2009) Risk of hip/femur fracture after stroke: a population-based case–control study. Stroke 40:3281–3285PubMedCrossRef Pouwels S, Lalmohamed A, Leufkens B, de Boer A, Cooper C, van Staa T et al (2009) Risk of hip/femur fracture after stroke: a population-based case–control study. Stroke 40:3281–3285PubMedCrossRef
15.
go back to reference de Vries F, Souverein PC, Cooper C, Leufkens HG, van Staa TP (2007) Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and the Netherlands. Calcif Tissue Int 80:69–75PubMedCrossRef de Vries F, Souverein PC, Cooper C, Leufkens HG, van Staa TP (2007) Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and the Netherlands. Calcif Tissue Int 80:69–75PubMedCrossRef
16.
go back to reference de Vries F, Pouwels S, Lammers JW, Leufkens HG, Bracke M, Cooper C et al (2007) Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case–control study. J Intern Med 261:170–177PubMed de Vries F, Pouwels S, Lammers JW, Leufkens HG, Bracke M, Cooper C et al (2007) Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case–control study. J Intern Med 261:170–177PubMed
17.
go back to reference de Vries F, Pouwels S, Bracke M, Leufkens HG, Cooper C, Lammers JW et al (2007) Use of beta-2 agonists and risk of hip/femur fracture: a population-based case–control study. Pharmacoepidemiol Drug Saf 16:612–619PubMedCrossRef de Vries F, Pouwels S, Bracke M, Leufkens HG, Cooper C, Lammers JW et al (2007) Use of beta-2 agonists and risk of hip/femur fracture: a population-based case–control study. Pharmacoepidemiol Drug Saf 16:612–619PubMedCrossRef
18.
go back to reference Arbouw ME, Movig KL, van Staa TP, Egberts AC, Souverein PC, de Vries F (2010) Dopaminergic drugs and the risk of hip or femur fracture: a population-based case–control study. Osteoporos Int 22:2197–204PubMedCrossRef Arbouw ME, Movig KL, van Staa TP, Egberts AC, Souverein PC, de Vries F (2010) Dopaminergic drugs and the risk of hip or femur fracture: a population-based case–control study. Osteoporos Int 22:2197–204PubMedCrossRef
19.
go back to reference Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N et al (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411PubMedCrossRef Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N et al (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411PubMedCrossRef
20.
go back to reference Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A et al (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669–674PubMedCrossRef Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A et al (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669–674PubMedCrossRef
21.
go back to reference Statistics Netherlands (2011) StatLine—hip fracture incidence rates, explanation methodology. Available at statline.cbs.nl. Accessed on 24 June 2011 Statistics Netherlands (2011) StatLine—hip fracture incidence rates, explanation methodology. Available at statline.​cbs.​nl. Accessed on 24 June 2011
22.
go back to reference McCloskey EV, Johansson H, Oden A, Kanis JA (2009) From relative risk to absolute fracture risk calculation: the FRAX algorithm. Curr Osteoporos Rep 7:77–83PubMedCrossRef McCloskey EV, Johansson H, Oden A, Kanis JA (2009) From relative risk to absolute fracture risk calculation: the FRAX algorithm. Curr Osteoporos Rep 7:77–83PubMedCrossRef
23.
go back to reference Kanis JA, on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical report. WHO Collaborating Centre, University of Sheffield, UK Kanis JA, on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical report. WHO Collaborating Centre, University of Sheffield, UK
24.
go back to reference Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Oglesby AK (2002) International variations in hip fracture probabilities; implications for risk assessment. J Bone Miner Res 17:1237–1244PubMedCrossRef Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Oglesby AK (2002) International variations in hip fracture probabilities; implications for risk assessment. J Bone Miner Res 17:1237–1244PubMedCrossRef
25.
go back to reference Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733PubMedCrossRef Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733PubMedCrossRef
26.
go back to reference Pluijm SM, Koes B, de Laet C, Van Schoor NM, Kuchuk NO, Rivadeneira F et al (2009) A simple risk score for the assessment of absolute fracture risk in general practice based on two longitudinal studies. J Bone Miner Res 24:768–774PubMedCrossRef Pluijm SM, Koes B, de Laet C, Van Schoor NM, Kuchuk NO, Rivadeneira F et al (2009) A simple risk score for the assessment of absolute fracture risk in general practice based on two longitudinal studies. J Bone Miner Res 24:768–774PubMedCrossRef
27.
go back to reference van Geel TA, Nguyen ND, Geusens PP, Center JR, Nguyen TV, Dinant GJ et al (2010) Development of a simple prognostic nomogram for individualising 5-year and 10-year absolute risks of fracture: a population-based prospective study among postmenopausal women. Ann Rheum Dis 70:92–97PubMedCrossRef van Geel TA, Nguyen ND, Geusens PP, Center JR, Nguyen TV, Dinant GJ et al (2010) Development of a simple prognostic nomogram for individualising 5-year and 10-year absolute risks of fracture: a population-based prospective study among postmenopausal women. Ann Rheum Dis 70:92–97PubMedCrossRef
28.
go back to reference Dutch Institute for Healthcare Improvement (CBO) (2011) Richtlijn Osteoporose en fractuurpreventie, derde herziening. CBO, Utrecht Dutch Institute for Healthcare Improvement (CBO) (2011) Richtlijn Osteoporose en fractuurpreventie, derde herziening. CBO, Utrecht
29.
go back to reference Yan L, Zhou B, Prentice A et al (1999) Epidemiological study of hip fracture in Shenyang Peoples Republic China. Bone 24:151–155PubMedCrossRef Yan L, Zhou B, Prentice A et al (1999) Epidemiological study of hip fracture in Shenyang Peoples Republic China. Bone 24:151–155PubMedCrossRef
30.
go back to reference Zingmond DS, Melton LJ III, Silverman SL (2004) Increasing hip fracture incidence in California Hispanics, 1983 to 2000. Osteoporos Int 15:603–610PubMedCrossRef Zingmond DS, Melton LJ III, Silverman SL (2004) Increasing hip fracture incidence in California Hispanics, 1983 to 2000. Osteoporos Int 15:603–610PubMedCrossRef
31.
go back to reference Morales Torres J, Gutierrez-Urena S (2004) The burden of osteoporosis in Latin America. Osteoporos Int 15:625–632PubMedCrossRef Morales Torres J, Gutierrez-Urena S (2004) The burden of osteoporosis in Latin America. Osteoporos Int 15:625–632PubMedCrossRef
32.
go back to reference Dennison E, Mohamed MA, Cooper C (2006) Epidemiology of osteoporosis. Rheum Dis Clin North Am 32:617–629PubMedCrossRef Dennison E, Mohamed MA, Cooper C (2006) Epidemiology of osteoporosis. Rheum Dis Clin North Am 32:617–629PubMedCrossRef
33.
go back to reference Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison EM, Melton LJ, Cummings SR, Kanis JA, and the IOF CSA Working Group on Fracture Epidemiology (2011) Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22:1277–1288PubMedCrossRef Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison EM, Melton LJ, Cummings SR, Kanis JA, and the IOF CSA Working Group on Fracture Epidemiology (2011) Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22:1277–1288PubMedCrossRef
34.
go back to reference Emaus N, Olsen LR, Ahmed LA, Balteskard L, Jacobsen BK, Magnus T et al (2011) Hip fractures in a city in Northern Norway over 15 years: time trends, seasonal variation and mortality: The Harstad Injury Prevention Study. Osteoporos Int 22:2603–2610PubMedCrossRef Emaus N, Olsen LR, Ahmed LA, Balteskard L, Jacobsen BK, Magnus T et al (2011) Hip fractures in a city in Northern Norway over 15 years: time trends, seasonal variation and mortality: The Harstad Injury Prevention Study. Osteoporos Int 22:2603–2610PubMedCrossRef
35.
go back to reference Juel K (2000) Increased mortality among Danish women: population based register stdy. BMJ 321:349–350PubMedCrossRef Juel K (2000) Increased mortality among Danish women: population based register stdy. BMJ 321:349–350PubMedCrossRef
36.
go back to reference Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D et al (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105–108PubMedCrossRef Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D et al (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105–108PubMedCrossRef
37.
go back to reference Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A et al (2008) Case finding for the management of osteoporosis with FRAX–assessment and intervention thresholds for the UK. Osteoporos Int 19:1395–1408PubMedCrossRef Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A et al (2008) Case finding for the management of osteoporosis with FRAX–assessment and intervention thresholds for the UK. Osteoporos Int 19:1395–1408PubMedCrossRef
38.
go back to reference Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD (2011) FRAX® with and without BMD. Calcif Tissue Int (In press) Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD (2011) FRAX® with and without BMD. Calcif Tissue Int (In press)
41.
go back to reference Fraser L-A, Langsetmo L, Berger C, IG Goltzman D, Adachi JD, and the CaMos Research Group et al (2011) Fracture prediction and calibration of a Canadian FRAX® tool; a population-based report from CaMos. Osteoporos Int 22:829–837PubMedCrossRef Fraser L-A, Langsetmo L, Berger C, IG Goltzman D, Adachi JD, and the CaMos Research Group et al (2011) Fracture prediction and calibration of a Canadian FRAX® tool; a population-based report from CaMos. Osteoporos Int 22:829–837PubMedCrossRef
42.
go back to reference Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2010) Manitoba bone density program. Independent clinical validation of a Canadian FRAX((R)) tool: fracture prediction and model calibration. J Bone Miner Res 25:2350–2358PubMedCrossRef Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA (2010) Manitoba bone density program. Independent clinical validation of a Canadian FRAX((R)) tool: fracture prediction and model calibration. J Bone Miner Res 25:2350–2358PubMedCrossRef
43.
go back to reference Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractures Scores. Br Med J 339:b4229CrossRef Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractures Scores. Br Med J 339:b4229CrossRef
44.
go back to reference Siris ES, Brenneman SK, Barrett-Connor E, Miller PD, Sajjan S, Berger ML et al (2006) The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50–99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int 17:565–574PubMedCrossRef Siris ES, Brenneman SK, Barrett-Connor E, Miller PD, Sajjan S, Berger ML et al (2006) The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50–99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int 17:565–574PubMedCrossRef
45.
go back to reference De Laet C, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330–1338PubMedCrossRef De Laet C, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330–1338PubMedCrossRef
46.
go back to reference van den Brand MW, Samson MM, Pouwels S, van Staa TP, Thio B, Cooper C et al (2009) Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporos Int 20:1705–1713PubMedCrossRef van den Brand MW, Samson MM, Pouwels S, van Staa TP, Thio B, Cooper C et al (2009) Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporos Int 20:1705–1713PubMedCrossRef
47.
go back to reference Cauley JA, Hochberg MC, Lui LY, Palermo L, Ensrud KE, Hillier TA et al (2007) Long-term risk of incident vertebral fractures. JAMA 298:2761PubMedCrossRef Cauley JA, Hochberg MC, Lui LY, Palermo L, Ensrud KE, Hillier TA et al (2007) Long-term risk of incident vertebral fractures. JAMA 298:2761PubMedCrossRef
48.
go back to reference van Helden S, Cals J, Kessels F, Brink P, Dinant GJ, Geusens P (2006) Risk of new clinical fractures within 2 years following a fracture. Osteoporos Int 17:348–354PubMedCrossRef van Helden S, Cals J, Kessels F, Brink P, Dinant GJ, Geusens P (2006) Risk of new clinical fractures within 2 years following a fracture. Osteoporos Int 17:348–354PubMedCrossRef
49.
go back to reference De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56:208–214PubMedCrossRef De Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, Van Staa TP (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56:208–214PubMedCrossRef
50.
go back to reference Leib ES, Saag KG, Adachi JD, Geusens PP, Binkley N, McCloskey EV et al (2011) Official positions for FRAX (®) clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX (®) of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX (®). J Clin Densitom 14:212–219PubMedCrossRef Leib ES, Saag KG, Adachi JD, Geusens PP, Binkley N, McCloskey EV et al (2011) Official positions for FRAX (®) clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX (®) of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX (®). J Clin Densitom 14:212–219PubMedCrossRef
51.
go back to reference Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809–816PubMedCrossRef Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809–816PubMedCrossRef
52.
go back to reference Hans DB, Kanis JA, Baim S, Bilezilian JP, Binkley N, Cauley JA et al (2011) Joint official positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX: executive summary of the 2010 Position Development Conference on Interpretation and Use of FRAX in Clinical Practice. J Clin Densitom 14:171–180PubMedCrossRef Hans DB, Kanis JA, Baim S, Bilezilian JP, Binkley N, Cauley JA et al (2011) Joint official positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX: executive summary of the 2010 Position Development Conference on Interpretation and Use of FRAX in Clinical Practice. J Clin Densitom 14:171–180PubMedCrossRef
Metadata
Title
Calibration of FRAX ® 3.1 to the Dutch population with data on the epidemiology of hip fractures
Authors
A. Lalmohamed
P. M. J. Welsing
W. F. Lems
J. W. G. Jacobs
J. A. Kanis
H. Johansson
A. De Boer
F. De Vries
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 3/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-011-1852-2

Other articles of this Issue 3/2012

Osteoporosis International 3/2012 Go to the issue